Home Opthea Limited

Opthea Limited

Final Patient Visit in Phase 2b Wet AMD Clinical Trial Completed

Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today that the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit.

Must Read

LifeSPARC Advanced Circulatory Support System

“LifeSPARC is the new generation pump and controller for the venerable Tandem system – a small but powerful heart pump with a magnetic bearing, a low-profile controller and a highly simplified user interface. I believe many more patients will have access to this higher level of support for the first time,” said Dr. David Baran, System Director for Advanced Heart Failure Transplant and Mechanical Circulatory Support at Sentara Heart Hospital in Norfolk, Va.

Endotronix Enrolls First Patient in SIRONA II CE Mark Trial

“SIRONA II builds on the success of our First-in-Human trial and expands our experience with the Cordella Sensor as we progress towards receiving our CE Mark,” stated Katrin Leadley, MD, Chief Medical Officer of Endotronix.

Joe Montana Professional Football Hall of Famer Joins Stimwave Technologies As Official Spokesperson

“After years of dealing with the residual effects of my professional football career, I am excited to have found this battery-free, minimally-invasive alternative to opioids that relieves chronic pain and I’m eager to help other chronic pain sufferers receive this life-changing micro-implant,” said Montana.